SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 Mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens; Overall Response Rate Of 56% Achieved To Date In Patient...
SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 Mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens; Overall Response Rate Of 56% Achieved To Date In Patient...
SELLAS Announces Median Overall Survival Not Yet Reached, Now Exceeds 7.7. Months At Latest Follow-Up In The 30 Mg BIW Cohort In Patients Relapsed Or Refractory To Venetoclax-Based Regimens; Overall Response Rate Of 56% Achieved To Date In Patient With Acute Myeloid Leukemia With Myelodysplasia Related Changes Prospectively Enrolled In Two Expansion Cohorts; Exceeding Prespecified Target Response Rate Of 33%
SELLAS宣布中位总体生存期尚未达到，最新跟进中在30毫克双周组的患者中超过7.7个月；截至目前，在前瞻性入组的急性髓性白血病伴有骨髓发育不良相关变化的患者中，总体反应率达到56%；超出预先设定的33%的目标反应率。
- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -
- 中位生存期(mOS)尚未达到，在最近的随访中，30 mg BIW组的患者中超过7.7个月。 -
- Overall Response Rate (ORR) of 56% Achieved to Date in Patient with Acute Myeloid Leukemia with Myelodysplasia Related Changes (AML MRC) Prospectively Enrolled in Two Expansion Cohorts; Exceeding Prespecified Target Response Rate of 33% -
- 截至目前，在急性髓性白血病伴有骨髓发育异常相关改变(AML MRC)的患者中，已达56%的总体响应率(ORR)，该患者是前瞻性登记在两个扩展队列中的；超过预设目标响应率33%。 -
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced additional data from the expansion cohorts in the Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia (r/r AML).
纽约，2024年12月9日（全球新闻通讯）——SELLAS生命科学集团公司（纳斯达克：SLS）（"SELLAS"或"公司"），是一家专注于开发广泛癌症适应症的新型疗法的晚期临床生物制药公司，今天宣布来自SLS009的扩展队列的额外数据，这是在复发/难治性急性髓性白血病（r/r AML）中使用的高度选择性的CDK9抑制剂的第2阶段试验。
